MaxCyteMXCT +3.54%62 Quick Ratio is 11.29 as of Mar. 2026, which is 11% above its 10-year median of 10.15. GuruFocus rates MXCT with a GF Score™ of 62/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, MaxCyte ranks better than 95.9% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. MaxCyte's quick ratio for the quarter that ended in Mar. 2026 was 11.29.
MaxCyte has a quick ratio of 11.29. It generally indicates good short-term financial strength.
The historical rank and industry rank for MaxCyte's Quick Ratio or its related term are showing as below:
MXCT'
s Quick Ratio Range Over the Past 10 Years
Min: 2.22 Med: 10.15 Max: 21.1
Current: 11.29
During the past 13 years, MaxCyte's highest Quick Ratio was 21.10. The lowest was 2.22. And the median was 10.15.
MXCT's Quick Ratio is ranked better than 95.9% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs MXCT: 11.29
MaxCyte (NAS:MXCT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
MaxCyte Quick Ratio Related Terms
MaxCyte Quick Ratio Historical Data
* Premium members only.
The historical data trend for MaxCyte's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MaxCyte's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Quick Ratio distribution charts can be found below:
* The bar in red indicates where MaxCyte's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
MaxCyte's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (MXCT) has a Quick Ratio of 11.29 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on MaxCyte and its competitors. This is 11% above median its historical median of 10.15. Over the past decade, MaxCyte's Quick Ratio has ranged from 2.22 to 21.10. According to the industry distribution chart, MaxCyte ranks #35 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 4.1%.
Is MaxCyte's Quick Ratio too high?
MaxCyte's current Quick Ratio of 11.29 is 11% above median its 10-year median of 10.15. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 21.10. The Medical Devices & Instruments industry median Quick Ratio is 1.87. MaxCyte's value of 11.29 is 505.4% above this industry median. Based on the distribution chart, MaxCyte ranks #35 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MaxCyte has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Quick Ratio compare to RCEL and NNOX?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #35 out of 854 companies for Quick Ratio. This places MaxCyte in the top 4% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.87. MaxCyte's value of 11.29 is 505.4% above this benchmark. Historically, MaxCyte's own Quick Ratio has ranged from 2.22 to 21.10 over the past decade. While the company's 10-year median is 10.15 vs. the industry median of 1.87, MaxCyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.87, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current Quick Ratio of 11.29 is 505.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Quick Ratio is 11.29, which is 11% above median its own 10-year median of 10.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.32 — trading 48.8% below its estimated fair value. The current Quick Ratio is 11.29, which is 11% above median its 10-year median of 10.15 and 505.4% above the Medical Devices & Instruments industry median of 1.87. MaxCyte's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For MaxCyte (MXCT), the current Quick Ratio is 11.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.32 is trading 48.8% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Quick Ratio: 11.29 (11% above median its 10-year median of 10.15)
GF Value™: $2.57 vs. price of $1.32 (48.8% below fair value)
Industry Position: 505.4% above the Medical Devices & Instruments median (#35 of 854)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
62GF Score
Get the complete analysis for MXCT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
